Please find enclosed herewith the Audited Results for the Quarter and Year Ended March, 2026, along with Auditor''s Report.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Parnax Lab reported mixed results for FY2026. On a consolidated basis, total revenue grew significantly to Rs. 25,232.56 lakhs from Rs. 18,041.44 lakhs in the prior year, driven by strong performance in the pharmaceutical formulations business. However, standalone revenue declined to Rs. 662.51 lakhs from Rs. 701.90 lakhs. Consolidated PAT grew marginally to Rs. 1,177.68 lakhs from Rs. 1,151.90 lakhs (approx 2.2% growth), while standalone PAT fell to Rs. 88.75 lakhs from Rs. 139.46 lakhs. The auditors issued an unmodified (clean) opinion on both standalone and consolidated financial results. Exceptional items of Rs. 136.93 lakhs (consolidated) and Rs. 3.49 lakhs (standalone) were recognised due to incremental impact of new labour codes on employee benefits like gratuity and compensated absences.
The large disparity between standalone and consolidated results suggests the subsidiary Naxpar Pharma Private Limited is the primary revenue driver. The marginal PAT growth despite strong revenue growth indicates margin compression at the consolidated level.